New Delhi, June 4 -- In a major development unveiled at the 2025 ASCO Annual Meeting, AstraZeneca's camizestrant, an investigational oral SERD (selective estrogen receptor degrader), has demonstrated remarkable efficacy in delaying disease progression in patients with hormone receptor-positive (HR-positive), HER2-negative advanced breast cancer, the most common subtype of breast cancer.

The findings stem from the SERENA-6 trial, which aimed to intercept cancer progression earlier than current treatment protocols by identifying ESR1 mutations before clinical symptoms appear. These mutations, which alter the estrogen receptor and drive resistance to standard hormone therapy, typically emerge after initial treatment with aromatase inhibitor...